{"id":"best-available-antiviral-drug-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL58301","moleculeType":"Small molecule","molecularWeight":"353.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug functions as a broad-spectrum antiviral agent, likely targeting conserved viral protease or polymerase enzymes that are critical for viral replication and spread. By blocking these key viral processes, the therapy reduces viral load and allows the immune system to control the infection more effectively.","oneSentence":"This antiviral therapy works by inhibiting viral replication through direct targeting of viral enzymes or proteins essential for the virus lifecycle.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:17.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral infections (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT02899065","phase":"NA","title":"Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2018-03-06","conditions":"Influenza, Human","enrollment":200},{"nctId":"NCT03339401","phase":"PHASE2","title":"The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-12-22","conditions":"Adenovirus","enrollment":29},{"nctId":"NCT04389944","phase":"NA","title":"Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-03-31","conditions":"Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)","enrollment":15},{"nctId":"NCT01220895","phase":"PHASE2","title":"Alternate Donor Study of Pre-Emptive Cellular Therapy","status":"COMPLETED","sponsor":"Cell Medica Ltd","startDate":"2010-10","conditions":"Cytomegalovirus Infection","enrollment":52},{"nctId":"NCT01077908","phase":"PHASE3","title":"Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study","status":"COMPLETED","sponsor":"Cell Medica Ltd","startDate":"2008-07","conditions":"Cytomegalovirus Infection","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Best available antiviral drug therapy","genericName":"Best available antiviral drug therapy","companyName":"Cell Medica Ltd","companyId":"cell-medica-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This antiviral therapy works by inhibiting viral replication through direct targeting of viral enzymes or proteins essential for the virus lifecycle. Used for Viral infections (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}